According to the latest announcement of Zhejiang Dean Diagnostic Technology Co., Ltd. (hereinafter referred to as Dean Diagnostics), on May 16, 2016, it cooperated with Deqing and Yingfu Investment Management Partnership (Limited Partnership) (hereinafter referred to as Yingfu Investment). Deqing Hejiaxin Investment Management Partnership (Limited Partnership) (hereinafter referred to as "Jiajiaxin Investment") signed the "Equity Transfer Agreement", stipulating that the company will use self-raised funds of RMB 253.5 million for transfer and Yingfu Investment and Hejiaxin Investment to hold the total Inner Mongolia Fengxin Medical Technology Co., Ltd. (hereinafter referred to as Fengxin Medical ) 65% of the shares.
Dean Diagnostics said that through this investment, the company will further promote the coverage and intensive cultivation of China's North China market, especially the Inner Mongolia market. Dean Diagnostics will establish and improve the business layout and market competitiveness of independent medical laboratories in Inner Mongolia, and continue to strengthen and upgrade the "service + product" integrated industrial model innovation and integrated marketing as a differentiated competitive strategy. The market in North China has achieved industrial chain integration and development.
Fengxin Medical is one of the most professional and largest companies selling medical inspection equipment in Inner Mongolia. Its business covers nearly 100 medical institutions in Inner Mongolia, providing high quality in vitro diagnostic products and expertise for medical institutions at all levels in Inner Mongolia. Comprehensive services such as support and logistics.
Dean’s “nationalization†strategy has been long-standing. In 2015, Dean Diagnostics acquired a 55% stake in Beijing Zhixin and a 55.79% stake in Jinhua Furida. In January and February this year, it announced the acquisition of a 51% stake in Xinjiang Yuanding and a 51% stake in Yunnan Shengshi Kehua. In a few days, it plans to acquire a 55% stake in Jiangxi Huaxing to lay out the East China market. It quickly integrates industry channel resources and leverages the customer resources and channel advantages of the invested companies to develop third-party medical diagnostic services in the business coverage area.
Dean Diagnostics Director Xu Min has said that in the future development of the company's core business independent medical laboratory, the company will adopt a combination of mergers and acquisitions and new construction to achieve rapid expansion of two to three families per year to complete the independent medical laboratory in the country. The layout, "Of course, in addition to the horizontal layout of the country, does not rule out the depth of the existing area to achieve intensive cultivation of the niche market."
As of the end of 2015, Dean Diagnostics has completed and has more than 26 laboratories under construction. The company's several large independent medical laboratories, such as Hangzhou, Nanjing, Beijing, and Shanghai, all have a scale of more than 100 million yuan.
According to Dean Diagnostics' 2015 annual report, the company's net profit has been growing at around 40% in recent years. In 2015, the company's total operating income reached 1.858 billion yuan, an increase of 39.18%. Among them, medical diagnostic services revenue was 1.08 billion yuan, an increase of 30.16%, and operating profit was 501 million yuan, an increase of 25.73%.
According to the Founder Securities Research Report, the global market for in vitro diagnostic demand is mainly distributed in developed economies such as North America, Europe, and Japan, accounting for more than 80% of the global market. The emerging economies of China, India, and Brazil have large population bases. The economic growth rate is high. In recent years, the continuous growth of medical insurance income and per capita medical consumption expenditure has driven the demand for in vitro diagnostic market. In 2012, the market size of China's in vitro diagnostic reagents exceeded 13.3 billion yuan. In 2015, the market scale doubled to 20.8 billion yuan. Therefore, the market has broad room for growth. It is expected that in vitro diagnostics will become the largest category of sales in the medical technology field in 2018. Sales will reach $54.5 billion.
Double Sided Nano Tape,Nano Double Sided Tape,Double Sided Magic Tape,Reusable Double Sided Tape
Kunshan Jieyudeng Intelligent Technology Co., Ltd. , https://www.jerrytapes.com